Omega-3 in SLE: A double-blind, placebo-controlled randomized clinical trial of endothelial dysfunction and disease activity in systemic lupus erythematosus

Rheumatology International

Volumn 33, Issue 11, 2013, Pages 2789-2796

  Bello, Kayode J ^a   Fang, Hong ^a   Fazeli, Parastoo ^b   Bolad, Waleed ^c   Corretti, Mary ^a   Magder, Laurence S ^d   Petri, Michelle ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Flow mediated dilation; LDL cholesterol; Omega 3; Systemic lupus erythematosus

Indexed keywords

INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OMEGA 3 ACID ETHYL ESTER; OMEGA 3 FATTY ACID; PLACEBO; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AFRICAN AMERICAN; ARTERY BLOOD FLOW; ARTERY DIAMETER; ARTERY DILATATION; ARTICLE; B SCAN; BRACHIAL ARTERY; CAUCASIAN; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIET RESTRICTION; DISEASE ACTIVITY; DISEASE MARKER; DOUBLE BLIND PROCEDURE; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM; FEMALE; FOLLOW UP; HUMAN; HYPEREMIA; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; ATHEROSCLEROSIS; BRACHIAL ARTERY; DOUBLE-BLIND METHOD; ENDOTHELIUM, VASCULAR; FATTY ACIDS, OMEGA-3; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84886721423     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-013-2811-3     Document Type: Article

References (51)

1. Artz MB, Harnack LJ, Duval SJ, Armstrong C, Arnett DK, Luepker RV (2006) Use of nonprescription medications for perceived cardiovascular health. Am J Prev Med 30:78-81
2. Leitzmann MF, Stampfer MJ, Michaud DS, Augustsson K, Colditz GC, Willett WC, et al. (2004) Dietary intake of n-3 and n-6 fatty acids and the risk of prostate cancer. Am J Clin Nutr 80:204-216
3. Caygill CP, Charlett A, Hill MJ (1996) Fat, fish, fish oil and cancer. Br J Cancer 74:159-164
4. Taepavarapruk P, Song C (2010) Reductions of acetylcholine release and nerve growth factor expression are correlated with memory impairment induced by interleukin-1beta administrations: effects of omega-3 fatty acid EPA treatment. J Neurochem 112:1054-1064
5. da Silva TM, Munhoz RP, Alvarez C, Naliwaiko K, Kiss A, Andreatini R, et al. (2008) Depression in Parkinson's disease: a double-blind, randomized, placebo-controlled pilot study of omega-3 fatty-acid supplementation. J Affect Disord 111:351-359
6. Iwami D, Nonomura K, Shirasugi N, Niimi M (2011) Immunomodulatory effects of eicosapentaenoic acid through induction of regulatory T cells. Int Immunopharmacol 11:384-389
7. Hao W, Wong OY, Liu X, Lee P, Chen Y, Wong KK (2010) ω-3 fatty acids suppress inflammatory cytokine production by macrophages and hepatocytes. J Pediatr Surg 45:2412-2418
8. Bucher HC, Hengstler P, Schindler C, Meier G (2002) N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials. Am J Med 112:298-304
9. Pignier C, Revenaz C, Rauly-Lestienne I, Cussac D, Delhon A, Gardette J, Le Grand B (2007) Direct protective effects of poly-unsaturated fatty acids, DHA and EPA, against activation of cardiac late sodium current: a mechanism for ischemia selectivity. Basic Res Cardiol 102:553-564
10. Iso H, Rexrode KM, Stampfer MJ, Manson JE, Colditz GA, Speizer FE, Hennekens CH, Willett WC (2001) Intake of fish and omega-3 fatty acids and risk of stroke in women. JAMA 285:304-312
11. Bang HO, Dyerberg J, Sinclair HM (1980) The composition of the Eskimo food in north western Greenland. Am J Clin Nutr 33:2657-2661
12. Kagawa Y, Nishizawa M, Suzuki M, Miyatake T, Hamamoto T, Goto K, et al. (1982) Eicosapolyenoic acids of serum lipids of Japanese islanders with low incidence of cardiovascular diseases. J Nutr Sci Vitaminol 28:441-453
13. Urowitz MB, Gladman DD, Abu-Shakra M, Farewell VT (1997) Mortality studies in systemic lupus erythematosus. Results from a single center. III. Improved survival over 24 years. J Rheumatol 24:1061-1065
14. Uramoto KM, Michet CJ Jr, Thumboo J, Sunku J, O'Fallon WM, Gabriel SE (1999) Trends in the incidence and mortality of systemic lupus erythematosus, 1950-1992. Arthritis Rheum 42:46-50
15. Kasitanon N, Magder LS, Petri M (2006) Predictors of survival in systemic lupus erythematosus. Medicine 85:147-156
16. Abu-Shakra M, Urowitz MB, Gladman DD, Gough J (1995) Mortality studies in systemic lupus erythematosus. Results from a single center. I. Causes of death. J Rheumatol 22:1259-1264
17. Björnådal L, Yin L, Granath F, Klareskog L, Ekbom A (2004) Cardiovascular disease a hazard despite improved prognosis in patients with systemic lupus erythematosus: results from a Swedish population based study 1964-95. J Rheumatol 31:713-719
18. Urowitz MB, Bookman AA, Koehler BE, Gordon DA, Smythe HA, Ogryzlo MA (1976) The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 60:221-225
19. Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger TA Jr Jansen-McWilliams L, et al. (1997) Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 145:408-415
20. Urowitz MB, Gladman DD (2000) Accelerated atheroma in lupus-background. Lupus 9:161-165
21. Hak AE, Karlson EW, Feskanich D, Stampfer MJ, Costenbader KH (2009) Systemic lupus erythematosus and the risk of cardiovascular disease: results from the nurses' health study. Arthritis Rheum 61:1396-1402
22. Jolly CA, Muthukumar A (2001) Reddy Avula CP, Fernandes G. Maintenance of NF-kappaB activation in T-lymphocytes and a naive T-cell population in autoimmune-prone (NZB/NZW)F(1) mice by feeding a food-restricted diet enriched with n-3 fatty acids. Cell Immunol 213:122-133
23. Fernandes G, Bysani C, Venkatraman JT, Tomar V, Zhao W (1994) Increased TGF-beta and decreased oncogene expression by omega-3 fatty acids in the spleen delays onset of autoimmune disease in B/W mice. J Immunol 152:5979-5987
24. Liang MH, Socher SA, Larsen MG, Schur PH (1989) Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 32:1107-1118
25. Duffy EM, Meenagh GK, McMillan SA, Strain JJ, Hannigan BM, Bell AL (2004) The clinical effect of dietary supplementation with omega-3 fish oils and/or copper in systemic lupus erythematosus. J Rheumatol 31:1551-1556
26. Hay EM, Bacon PA, Gordon C, Isenberg DA, Maddison P, Snaith ML, et al. (1993) The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 86:447-458
27. Wright SA, O'Prey FM, McHenry MT, Leahey WJ, Devine AB, Duffy EM, et al. (2008) A randomised interventional trial of omega-3-polyunsaturated fatty acids on endothelial function and disease activity in systemic lupus erythematosus. Ann Rheum Dis 67:841-848
28. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271-1277
29. Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725
30. Petri M, Kim MY, Kalunian KC, Grossman J, Hahn BH, Sammaritano LR, et al. (2005) OC-SELENA Trial. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 353:2550-2558
31. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA (2002) International Brachial Artery Reactivity Task Force. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 39:257-265
32. Corretti MC, Plotnick GD, Vogel RA (1995) Technical aspects of evaluating brachial artery vasodilatation using high-frequency ultrasound. Am J Physiol 268:1397-1404
33. Vogel RA, Corretti MC, Plotnick GD (2000) A comparison of brachial artery flow-mediated vasodilation using upper and lower arm arterial occlusion in subjects with and without coronary risk factors. Clin Cardiol 23:571-575
34. Lima DS, Sato EI, Lima VC, Miranda F Jr, Hatta FH (2002) Brachial endothelial function is impaired in patients with systemic lupus erythematosus. J Rheumatol 29:292-297
35. Johnson SR, Harvey PJ, Floras JS, Iwanochko M, Ibanez D, Gladman DD, Urowitz M (2004) Impaired brachial artery endothelium dependent flow mediated dilation in systemic lupus erythematosus: preliminary observations. Lupus 13:590-593
36. Mak A, Liu Y, Ho RC (2011) Endothelium-dependent but not endothelium-independent flow-mediated dilation is significantly reduced in patients with systemic lupus erythematosus without vascular events: a metaanalysis and metaregression. J Rheumatol 38:1296-1303
37. Bozcali E, Babalik E, Himmetoglu S, Mihmanli I, Toprak S (2013) [Omega]-3 fatty acid treatment in cardiac syndrome X: a double-blind, randomized, placebo-controlled clinical study. Coron Artery Dis 24:328-333
38. Rizos EC, Ntzani EE, Bika E, Kostapanos MS, Elisaf MS (2012) Association between Omega-3 fatty acid supplementation and risk of major cardiovascular disease events. JAMA 308:1024-1033
39. Pownall JH, Brauchi D, Kilinc C, Osmundsen K, Pao Q, Payton-Ross C, et al. (1999) Correlation of serum triglyceride and its reduction by ω-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins. Arterioscler 143:285-297
40. Harris WS, Ginsberg HN, Arunakul N, Shachter NS, Windsor SL, Adams M, et al. (1997) Safety and efficacy of Omacor in severe hypertriglyceridemia. J Cardiovasc Risk 4:385-391
41. Kiani AN, Post WS, Magder LS, Petri M (2011) Predictors of progression in atherosclerosis over 2 years in systemic lupus erythematosus. Rheumatology 50:2071-2079
42. ® [package insert]. GlaxoSmithKline, St. Petersburg, FL; December 2010
43. Contacos C, Barter PJ, Sullivan DR (1993) Effect of pravastatin and omega-3 fatty acids on plasma lipids and lipoproteins in patients with combined hyperlipidemia. Arterioscler Thromb 13:1755-1762
44. Suzukawa M, Abbey M, Howe PR, Nestel PJ (1995) Effects of fish oil fatty acids on low density lipoprotein size, oxidizability, and uptake by macrophages. J Lipid Res 36:473-484
45. Mori TA, Burke V, Puddey IB, Watts GF, O'Neal DN, Best JD, Beilin LJ (2000) Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men. Am J Clin Nutr 71:1085-1094
46. Campos H, Genest JJ Jr, Blijlevens E, et al. (1992) Low density lipoprotein particle size and coronary artery disease. Arterioscler Thromb 12:187-195
47. Hahn BH, Grossman J, Ansell BJ, Skaggs BJ, McMahon M (2008) Altered lipoprotein metabolism in chronic inflammatory states: proinflammatory high-density lipoprotein and accelerated atherosclerosis in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther 10:213
48. Simopoulos AP (2008) The importance of the omega-6/omega-3 fatty acid ratio in cardiovascular disease and other chronic diseases. Exp Biol Med 233:674-688
49. Cleland LG, James MJ, Neumann MA, D'Angelo M, Gibson RA (1992) Linoleate inhibits EPA incorporation from dietary fish-oil supplements in human subjects. Am J Clin Nutr 55:395-399
50. Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammaritano L, Simantov R, et al. (2003) Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 349:2399-2406
51. Zonana-Nacach A, Barr SG, Magder LS, Petri M (2000) Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum 43:1801-1808 Skin Diseases